Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Status:
Recruiting
Trial end date:
2028-08-27
Target enrollment:
Participant gender:
Summary
This is a phase II interventional study evaluating the use of minimal residual disease by
next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT)
in patients with newly diagnosed multiple myeloma.